『Excellent blood pressure lowering agent with heart and kidney protective effects

‘Waltrep Series’ released 』



KyungDong Pharm Co., Ltd. launches the ‘Valtrep Series’, an ARB-based blood pressure lowering drug, on November 12, 2011. The ‘Valtrep Series’, which contains Valsartan as its main ingredient, is scheduled to be released in a total of 4 products, including single drugs and combination drugs.

 

The Valtrep series shows an excellent blood pressure lowering effect compared to other ARB blood pressure lowering drugs, Olmesartan and Telmisartan, and has the additional effect of protecting the heart and kidneys. In addition, it has secured the largest amount of clinical data among the ARB series and has been proven to be a safer drug. In addition, it is the first ARB drug to demonstrate not only a blood pressure lowering effect but also a cardiovascular protection effect in a clinical study targeting Asians (Kyoto Heart Study).

 

With the launch of the ‘Valtrep Series’, KyungDong Pharm Co., Ltd. will have a total of four series of ARB blood pressure lowering drugs, following the ‘Losata Series’ containing losartan ingredients, the ‘Cansata Series’ containing candesartan ingredients, and the ‘Irbetan Series’ containing irbesartan ingredients. By possessing a variety of ARB products, we expect KyungDong Pharm Co., Ltd. to further solidify its position as a company specializing in hypertension treatment in the future.

 

♤ Product Information ♤


Category

Valtrep tablets 80mg

Valtrep tablets 160mg

Valtrep Plus Tab.

Valtrep Plus F Tab.

ingredient

content

Valsartan 80mg

Valsartan 160mg

Valsartan 80mg

Hydrochlorothiazide

12.5mg

Valsartan 160mg

Hydrochlorothiazide

12.5mg

Appearance

A bright pink, round, film-coated tablet with a score line on one side.

A grayish-orange, oval, film-coated tablet.

light pink oval

Film coated tablets

Dark red oval film-coated tablets

Indications

1. Essential hypertension

2. Heart failure - Heart failure intolerant to angiotensin converting enzyme inhibitors (NYHA class Ⅱ~IV)

3. Reduced risk of death after myocardial infarction

- Reduced risk of death after myocardial infarction in clinically stable patients with signs, symptoms, or radiological evidence of left ventricular dysfunction and/or left ventricular systolic dysfunction.

Essential hypertension whose blood pressure is not adequately controlled with monotherapy

packaging

unit

30 tablets

insurance

code

648103090

648102940

648103110

648103100

 

※ Please refer to the product manual for other details such as precautions for use.